Azelaic acid 15% gel for treatment of rosacea

Expert Review of Dermatology

Volumn 1, Issue 4, 2006, Pages 535-545

  Elewski, Boni E ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

azelaic acid; erythema; gel; metronidazole; papulopustular; rosacea

Indexed keywords

EID: 55249083073     PISSN: 17469872     EISSN: 17469880     Source Type: Journal    
DOI: 10.1586/17469872.1.4.535     Document Type: Article

References (51)

1. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J. Am. Acad. Dermatol. 51, 327–341 (2004).
2. Powell FC. Rosacea. N. Engl. J. Med. 352, 793–803 (2005).
3. Berg M, Liden S. An epidemiological study of rosacea. Acta Derm. Venereol. 69, 419–423 (1989).
4. Wilkin J, Dahl M, Detmar M et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J. Am. Acad. Dermatol. 46, 584–587 (2002).
5. Wilkin J, Dahl M, Detmar M et al. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J. Am. Acad. Dermatol. 50, 907–912 (2004).
6. Blount BW, Pelletier AL. Rosacea: a common, yet commonly overlooked, condition. Am. Fam. Physician 66, 435–440 (2002).
7. Fleischer A, Suephy C. The face and mind evaluation study: an examination of the efficacy of rosacea treatment using physician ratings and patients’ self-reported quality of life. J. Drugs Dermatol. 4, 585–590 (2005).
8. Miyachi Y, Imamura S, Niwa Y. Anti-oxidant action of metronidazole: a possible mechanism of action in rosacea. Br. J. Dermatol. 114, 231–234 (1986).
9. Miyachi Y. Potential antioxidant mechanisms of action for metronidazole: implications for rosacea management. Adv. Ther. 18, 237–243 (2001).
10. Millikan L. The proposed inflammatory pathophysiology of rosacea: implications for treatment. Skinmed 2, 43–47 (2003).
11. Passi S, Picardo M, Zompetta C, De Luca C, Breathnach AS, Nazzaro-Porro M. The oxyradical-scavenging activity of azelaic acid in biological systems. Free Radic. Res. Commun. 15, 17–28 (1991).
12. Akamatsu H, Komura J, Asada Y, Miyachi Y, Niwa Y. Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases. Arch. Dermatol. Res. 283, 162–166 (1991).
13. Jones D. Reactive oxygen species and rosacea. Cutis 74 (Suppl. 3), 17–20, 3234 (2004).
14. Dahl MV. Pathogenesis of rosacea. Adv. Dermatol. 17, 29–45 (2001).
15. Nielsen PG. Treatment of rosacea with 1% metronidazole cream. A double-blind study. Br. J. Dermatol. 108, 327–332 (1983).
16. Bikowski JB, Goldman MP. Rosacea: where are we now? J. Drugs Dermatol. 3, 251–261 (2004).
17. Wolf JE Jr. The role of topical metronidazole in the treatment of rosacea. Cutis 73 (Suppl. 1), 19–28 (2004).
18. Ziel K, Yelverton CB, Balkrishnan R, Feldman SR. Cumulative irritation potential of metronidazole gel compared to azelaic acid gel after repeated applications to healthy skin. J. Drugs Dermatol. 4, 727–731 (2005).
19. Del Rosso JQ. Medical treatment of rosacea with emphasis on topical therapies. Expert Opin. Pharmacother. 5, 5–13 (2004).
20. No authors listed. Azelaic acid (Finacea) for rosacea. Med. Lett. Drugs Ther. 45, 76–77 (2003).
21. Van Landuyt H, Joubert-Lequain I, Humbert P et al. Treatment of rosacea. Clonidine (0.075 mg per day) versus placebo (initial results). Ann. Dermatol. Venereol. 124, 729 (1997).
22. Grosshans E, Michel C, Arcade B, Cribier B. Rilmenidine in rosacea: a double-blind study versus placebo. Ann. Dermatol. Venereol. 124, 687–691 (1997).
23. Wilkin JK. Effect of nadolol on flushing reactions in rosacea. J. Am. Acad. Dermatol. 20, 202–205 (1989).
24. Detmar M. The role of VEGF and thrombospondins in skin angiogenesis. J. Dermatol. Sci. 24 (Suppl. 1), S78 –S84 (2000).
25. Kocak M, Yagli S, Vahapoglu G, Eksioglu M. Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. A randomized double-blind placebo-controlled study. Dermatology 205, 265–270 (2002).
26. Clyti E, Sayavong K, Chanthavisouk K. Demodecidosis in a patient infected by HIV: successful treatment with ivermectin. Ann. Dermatol. Venereol. 132, 459–461 (2005).
27. Forton F, Germaux MA, Brasseur T et al. Demodicosis and rosacea: epidemiology and significance in daily dermatologic practice. J. Am. Acad. Dermatol. 52, 74–87 (2005).
28. Nazzaro-Porro M, Passi S. Effetto degli acidi dicarbossilici in alcune dermatosi pigmentarie. G. Ital. Dermatol. 113, 401–404 (1978).
29. Nazzaro-Porro M, Passi S, Picardo M, Breathnach A, Clayton R, Zina G. Beneficial effect of 15% azelaic acid cream on acne vulgaris. Br. J. Dermatol. 109, 45–48 (1983).
30. Guttman C. Rosacea relief: Finacea represents FDA’s first rosacea Tx approval in decade. Dermatol. Times February 1 (2003).
31. Draelos ZD, Graupe K. A new topical formulation for the treatment of mild to moderate papulopustular rosacea: azelaic acid 15% gel. Proceedings of the American Academy of Dermatology 61st Annual Meeting. CA, USA, Poster 49 (2003).
32. Topert M, Rach P, Siegmund F. Pharmacology and toxicology of azelaic acid. Acta Derm. Venereol. 143 (Suppl.), 14–19 (1989).
33. Picardo M, Passi S, Sirianni MC et al. Activity of azelaic acid on cultures of lymphoma- and leukemia-derived cell lines, normal resting and stimulated lymphocytes and 3T3 fibroblasts. Biochem. Pharmacol. 34, 1653–1658 (1985).
34. Leibl H, Stingl G, Pehamberger H, Korschan H, Konrad K, Wolff K. Inhibition of DNA synthesis of melanoma cells by azelaic acid. J. Invest. Dermatol. 85, 417–422 (1985).
35. Schallreuter KU, Wood JM. Azelaic acid as a competitive inhibitor of thioredoxin reductase in human melanoma cells. Cancer Lett. 36, 297–305 (1987).
36. Breathnach AS. Azelaic acid: potential as a general antitumoural agent. Med. Hypotheses 52, 221–226 (1999).
37. Nazzaro-Porro M. Azelaic acid. J. Am. Acad. Dermatol. 17, 1033–1041 (1987).
38. Brasch J, Christophers E. Azelaic acid has antimycotic properties in vitro. Dermatology 186, 55–58 (1993).
39. Leeming JP, Holland KT, Bojar RA. The in vitro antimicrobial effect of azelaic acid. Br. J. Dermatol. 115, 551–556 (1986).
40. Tauber U, Weiss C, Matthes H. Percutaneous absorption of azelaic acid in humans. Exp. Dermatol. 1, 176–179 (1992).
41. Bojar RA, Cutliffe AG, Graupe K, Cunliffe WJ, Holland KT. Follicular concentrations of azelaic acid after a single topical application. Br. J. Dermatol. 129, 399–402 (1993).
42. Passi S, Picardo M, Mingrone G, Breathnach AS, Nazzaro-Porro M. Azelaic acid–biochemistry and metabolism. Acta Derm. Venereol. 143 (Suppl.), 8–13 (1989).
43. Passi S, Picardo M, De Luca C, Breathnach AS, Nazzaro-Porro M. Scavenging activity of azelaic acid on hydroxyl radicals “in vitro.” Free Radic. Res. Commun. 1, 329–338 (1991).
44. Nazzaro-Porro M, Passi S, Picardo M, Balus L, Breathnach AS. Azelaic acid in rosacea? G. Ital. Dermatol. Venerol. 126, 19–27 (1991).
45. Carmichael AJ, Marks R, Graupe KA, Zaumseil RP. Topical azelaic acid in the treatment of rosacea. J. Dermatol. Treat. 4 (Suppl. 1), S19 –S22 (1993).
46. Bjerke R, Fryand O, Graupe K. Double-blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo-pustular rosacea. Acta Derm. Venereol. 79, 456–459 (1999).
47. Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J. Am. Acad. Dermatol. 40, 961–965 (1999).
48. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized Phase III studies. J. Am. Acad. Dermatol. 48, 836–845 (2003).
49. Elewski BE, Fleischer AB Jr, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch. Dermatol. 139, 1444–1450 (2003).
50. Wolf JE, Kerrouche N, Arsonnaud S. Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. Cutis 77 (Suppl. 4), 3–11 (2006).
51. Draelos ZD. Noxious sensory perceptions in patients with mild to moderate rosacea treated with azelaic acid 15% gel. Cutis 74, 257–260 (2004).